Odomzo
sonidegib · Sun Pharmaceutical Industries Europe B.V.
AUTHORISED IN THE EUWhat Odomzo is used for
Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Odomzo
- Active substance
- sonidegib
- Disease area
- Carcinoma, Basal Cell
- Medicine group
- Antineoplastic agents
- ATC code
- L01XJ02
- Marketing authorisation holder
- Sun Pharmaceutical Industries Europe B.V.
- Authorised in the EU since
- 2015
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Odomzo used for?
Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy.
What is the active substance in Odomzo?
Odomzo contains sonidegib.
Who makes Odomzo?
The EU marketing authorisation holder is Sun Pharmaceutical Industries Europe B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU